8:30-9:00 Registration and breakfast

9:00-11:30 Two concurrent sessions

Session B (MDS/AML/MPN/ALL)

9:00-10:00 Clinical controversies in acute leukemia 

Lydia Benitez, PharmD, BCOP, Michigan Medicine, Pharmacy

Patrick Burke, MD, Michigan Medicine, Division of Hematology Oncology

Bernard Marini, PharmD, BCOP, Michigan Medicine, Pharmacy

Anthony Perissinotti, PharmD, BCOP, Michigan Medicine, Pharmacy

10:00-10:20     Update in myelofibrosis

Moshe Talpaz, MD, Michigan Medicine, Division of Hematology Oncology

10:20-10:50     Clonal hematopoiesis

Morgan Jones MD, PhD, Michigan Medicine, Division of Hematology Oncology

10:50-11:20     ET/PV: New treatments on the horizon, but who needs treatment?

Kristen Pettit, MD, Michigan Medicine, Division of Hematology Oncology

11:30-12:30 Lunch available

12:00-1:00 Keynote Address - Current Approaches in Frontline CLL

Jennifer Woyach, MD

Professor and Director of the Division of Hematology

D Warren Brown Chair of Leukemia Research

Co-Director of the Leukemia Research Program, OSU Comprehensive Cancer Center

1:00-3:30 Two concurrent sessions

Session A (Lymphoma II)

1:00-2:00 Panel Discussion. Drs. Karimi, Sano, Carty, Weiss, Phillips: Audience provided cases/questions

Moderator: Ryan Wilcox, MD, PhD; Michigan Medicine, Division of  Hematology/Oncology

2:00-2:30 Diffuse Large B-Cell Lymphoma 

Yasmin Karimi, MD, Michigan Medicine, Division of Hematology Oncology

2:30-3:00 Immunodeficiency-associated NHL

Shannon Carty, MD, Michigan Medicine, Division of Hematology Oncology

3:00-3:30     Updates in Follicular Lymphoma  

Jonathan Weiss, MD, Michigan Medicine, Division of Hematology Oncology

Session B (Myeloma)

1:00-2:00 AL Amyloidosis: Beyond ANDROMEDA 

Jeffrey Zonder, MD, Karmanos Cancer Institute, Wayne State University

2:00-2:45    Where to Park the CAR?  Balancing Cell Therapy Response and Toxicity in  Multiple Myeloma 

Marcus Geer, MD, Michigan Medicine, Division of Hematology Oncology

2:45-3:30 Management of Multiple Myeloma in 2025: State of the Art 

Matthew Pianko, MD, Michigan Medicine, Division of Hematology Oncology

7:00-8:00 Registration and Continental Breakfast

8:00-8:05 Welcome

Ryan Wilcox, MD, PhD
Michigan Medicine, Division of Hematology Oncology; Section Head, Lymphoma and Myeloma

8:05-8:30 My Patient has a T-Cell Lymphoma, Now What?

Ryan Wilcox, MD, PhD

8:30-9:00 DLBCL Management: A State-of-the-Art Review

Yasmin Karimi, MD
Michigan Medicine, Division of Hematology Oncology

9:00-9:30 The Road There and Back Again. The Journey of Immunotherapy in Lymphoma

Tycel Phillips, MD
City of Hope Comprehensive Cancer Center, Los Angeles, CA

9:30-10:00 Frontline Management of Myeloma: A State-of-the-Art Review

Matt Pianko, MD
Michigan Medicine, Division of Hematology Oncology

10:00-10:30 Coffee Break and Networking

10:40-11:10 Advances in the Management of Relapsed/ refractory Myeloma

Erica Campagnaro, MD
Michigan Medicine, Division of Hematology Oncology

11:10-11:40 Advances in CAR T-cell Therapy for Lymphoma

Monalisa Ghosh, MD
Michigan Medicine, Division of Hematology Oncology

12:00-1:00 Buffet Lunch

1:00-2:00 Keynote Address: Myeloproliferative Neoplasms: 2023 update

Ayalew Tefferi, MD
Barbara Woodward Lips Professor of Medicine, Mayo Clinic, Division of Hematology, Rochester, MN

2:00-2:20 Clinical Debates in AML

Dale Bixby, MD, PhD, Michigan Medicine, Division of Hematology Oncology
Bernard Marini, PharmD,  Michigan Medicine, Pharmacy

Anthony Perissinotti, PharmD, Michigan Medicine, Pharmacy

2:40-3:05 CML: Past and Present

Moshe Talpaz, MD
Michigan Medicine, Division of Hematology Oncology

Alexander J. Trotman Professor for Leukemia Research, Associate Division Chief for Hematology

3:05-3:30 Challenging MPN Cases

Kristen Pettit, MD
Michigan Medicine, Division of Hematology Oncology

3:30-3:40 Closing Remarks

Moshe Talpaz, MD

3:40-4:30 Hors d’oeuvres and Networking Reception